Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hegde

Showing results (641-650 of 657) with videos related to

Pageof 66
Sort By:
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Bone Marrow Transplantation|November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Plos One|May 16, 2024
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumorsDaniel R Zollinger, Elizabeth Rivers, Alexander Fine, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockadeRomain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Nature Genetics|October 2, 2012
Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48Saima Riazuddin, Inna A Belyantseva, Arnaud P J Giese, et al.
Pageof 66

Showing results (641-650 of 657) with videos related to

Sort By:
Pageof 66
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Nature Medicine|May 15, 2020
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockadeKobe C Yuen, Li-Fen Liu, Vinita Gupta, et al.
Bone Marrow Transplantation|November 6, 2024
Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Bone Marrow Transplantation|October 25, 2024
Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemiaGege Gui, Niveditha Ravindra, Pranay S Hegde, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The Journal of Clinical Investigation|August 16, 2013
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Mahrukh Huseni, Tanya Smyczek, et al.
Plos One|May 16, 2024
Analytical validation of a novel comprehensive genomic profiling informed circulating tumor DNA monitoring assay for solid tumorsDaniel R Zollinger, Elizabeth Rivers, Alexander Fine, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockadeRomain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Nature Genetics|October 2, 2012
Alterations of the CIB2 calcium- and integrin-binding protein cause Usher syndrome type 1J and nonsyndromic deafness DFNB48Saima Riazuddin, Inna A Belyantseva, Arnaud P J Giese, et al.
Pageof 66